Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urological Physicians of San Diego, Inc.
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urological Physicians of San Diego, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Medical Oncology Associates - SD
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Medical Oncology Associates - SD
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Sharp Memorial Hospital Investigational Pharmacy
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Sharp Memorial Hospital Investigational Pharmacy
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Sharp Rees-Stealy
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Sharp Rees-Stealy
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Pacific Clinical Research
mi
from
Santa Monica, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Pacific Clinical Research
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Agajanian Institute of Oncology and Hematology
mi
from
Whittier, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Agajanian Institute of Oncology and Hematology
mi
from
Whittier, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Porter Adventist Hospital
mi
from
Denver, CO
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urology Associates, PC
mi
from
Denver, CO
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urology Associates, PC
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Diagnostic Professionals, Inc
mi
from
Plantation, FL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Diagnostic Professionals, Inc
mi
from
Plantation, FL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southeastern Resarch Group, Inc.
mi
from
Tallahassee, FL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southeastern Resarch Group, Inc.
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
St. Alphonsus Regional Medical Center
mi
from
Boise, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
St. Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
North Idaho Urology
mi
from
Coeur d'Alene, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
North Idaho Urology
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Idaho Urologic Institute, P.A.
mi
from
Meridian, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Idaho Urologic Institute, P.A.
mi
from
Meridian, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
North Idaho Urology
mi
from
Sandpoint, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
North Idaho Urology
mi
from
Sandpoint, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
University of Chicago
mi
from
Chicago, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
OSF St Mary Medical Center
mi
from
Galesburg, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
OSF St Mary Medical Center
mi
from
Galesburg, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Midwest Urology/RMD Clinical Research Institute
mi
from
Melrose Park, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Midwest Urology/RMD Clinical Research Institute
mi
from
Melrose Park, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Johns Hopkins
mi
from
Baltimore, MD
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
AdvanceMed Research
mi
from
Lawrenceville, NJ
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
AdvanceMed Research
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urology Group of New Mexico
mi
from
Albuquerque, NM
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urology Group of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Community Care Physicians, PC / The Urological Institute of Northeastern New York
mi
from
Albany, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Community Care Physicians, PC / The Urological Institute of Northeastern New York
mi
from
Albany, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Beth Israel Med Ctr
mi
from
New York, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
University Urological Associates
mi
from
New York, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
University Urological Associates
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Staten Island Urological Research, PC
mi
from
Staten Island, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Staten Island Urological Research, PC
mi
from
Staten Island, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Wake Urological Associates
mi
from
Raleigh, NC
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Wake Urological Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urologic Consultants of SE PA
mi
from
Bala Cynwyd, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urologic Consultants of SE PA
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Center for Urologic Care of the Main Line
mi
from
Bryn Mawr, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Center for Urologic Care of the Main Line
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urological Associates of Lancaster
mi
from
Lancaster, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urological Associates of Lancaster
mi
from
Lancaster, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
University of Pittsburgh Physicians, Department of Urology
mi
from
Pittsburgh, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
University of Pittsburgh Physicians, Department of Urology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Virginia Oncology Associates
mi
from
Hampton, VA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Virginia Oncology Associates
mi
from
Hampton, VA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Virginia Oncology Associates
mi
from
Newport News, VA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Virginia Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Seattle Urology Research Center
mi
from
Burien, WA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Seattle Urology Research Center
mi
from
Burien, WA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Roger D. Fincher, PS
mi
from
Spokane, WA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Roger D. Fincher, PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Andreou Research
mi
from
Surrey,
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Andreou Research
mi
from
Surrey,
Click here to add this to my saved trials
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back
Status: Enrolling
Updated:  10/5/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back
Status: Enrolling
Updated: 10/5/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck
Status: Enrolling
Updated:  10/5/2015
Cancer Treatment Centers of American Western Regional Medical Center
mi
from
Goodyear, AZ
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck
Status: Enrolling
Updated: 10/5/2015
Cancer Treatment Centers of American Western Regional Medical Center
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck
Status: Enrolling
Updated:  10/5/2015
Baylor College of Medicine
mi
from
Houston, TX
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck
Status: Enrolling
Updated: 10/5/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy
Status: Enrolling
Updated:  10/5/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy
Status: Enrolling
Updated: 10/5/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Docetaxel and Sirolimus in Patients With Advanced Malignancies
A Phase I Trial of Docetaxel and Sirolimus in Patients With Advanced Malignancies
Status: Enrolling
Updated:  10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Docetaxel and Sirolimus in Patients With Advanced Malignancies
A Phase I Trial of Docetaxel and Sirolimus in Patients With Advanced Malignancies
Status: Enrolling
Updated: 10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials